The Trump administration and state governments are taking action on drug pricing. Keep up with our comprehensive coverage of administrative and legislative activity and what it means for industry, plans, providers, and patients.
The shift from volume to value has played a significant role in shaping current payer behavior in the oncology space.
Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.
User fees are increasingly central to the funding of the drug and device review programs, and in some cases these fees account for a larger proportion of the Food and Drug Administration's (FDA) budget than congressionally-appropriated monies. For example, user fees account for 68 percent of the FDA's review budget for prescription drugs, while 58 percent of the review budget for generic drugs comes from user fees.